Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.59 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 3/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407982 | 0.96 | TGFBR1 (0.60) | TGFBR1TGFBR2THRBMAPK14 | |
| SCHEMBL413261 | 0.92 | TGFBR1 (0.63) | TGFBR1TGFBR2THRBMAPK14 | |
| SCHEMBL413616 | 0.92 | TGFBR1 (0.64) | TGFBR1TGFBR2 | |
| SCHEMBL14198366 | 0.91 | TGFBR1 (0.55) | TGFBR1TGFBR2THRBMAPK14 | |
| SCHEMBL411839 | 0.89 | TGFBR1 (0.67) | TGFBR1TGFBR2THRBMAPK14 | |
| SCHEMBL4871905 | 0.88 | TGFBR1 (0.60) | TGFBR1TGFBR2THRBMAPK14 | |
| SCHEMBL4872336 | 0.88 | TGFBR1 (0.51) | TGFBR1TGFBR2THRBMAPK14 | |
| SCHEMBL412954 | 0.86 | TGFBR1 (0.55) | TGFBR1TGFBR2THRBMAPK14 | |
| SCHEMBL16296983 | 0.86 | TGFBR1 (0.53) | TGFBR1TGFBR2THRBMAPK14 | |
| SCHEMBL4871888 | 0.86 | TGFBR1 (0.55) | TGFBR1TGFBR2THRBMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365066-B2 | Pyrazolopyridine derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-04-29 | — | — | US | claimed |
| EP-1543001-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2007-08-15 | — | — | EP | claimed |
| US-20050222197-A1 | Novel pyrazolopyridine derivatives as pharmaceutical agents | BEIGHT DOUGLAS W | 2005-10-06 | — | — | US | claimed |
| EP-1543001-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2005-06-22 | — | — | EP | claimed |
| WO-2004026871-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | claimed |
| US-7365066-B2 | Pyrazolopyridine derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365066-B2 | Pyrazolopyridine derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365066-B2 | Pyrazolopyridine derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1543001-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1543001-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20050222197-A1 | Novel pyrazolopyridine derivatives as pharmaceutical agents | BEIGHT DOUGLAS W | 2005-10-06 | — | — | US | disclosed |
| EP-1543001-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004026871-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222197-A1 | Novel pyrazolopyridine derivatives as pharmaceutical agents | TGFB2, TGFB1, TGFBR1 | TGFBR1 3/4885TGFBR2 6/4885THRB 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.